Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?

Company Performance - Phibro Animal Health (PAHC) shares have increased by 9.5% over the past month, reaching a new 52-week high of $26.77 [1] - Year-to-date, Phibro has gained 26.8%, outperforming the Zacks Medical sector, which saw a decline of 2.7%, and the Zacks Medical - Products industry, which returned 7.6% [1] Earnings and Revenue - Phibro has consistently exceeded earnings consensus estimates, reporting EPS of $0.63 against a consensus of $0.52 in its last earnings report [2] - For the current fiscal year, Phibro is projected to earn $2.29 per share on revenues of $1.28 billion, with a year-over-year earnings growth of 12.5% [3] - The next fiscal year earnings are expected to be $2.52 per share on revenues of $1.41 billion, reflecting a growth of 10.35% [3] Valuation Metrics - Phibro's current trading valuation is at 11.6X current fiscal year EPS estimates, significantly lower than the peer industry average of 19.5X [7] - The stock has a trailing cash flow valuation of 12.6X compared to the peer group's average of 10.9X, and a PEG ratio of 0.45, indicating strong value potential [7] Zacks Rank and Style Scores - Phibro holds a Zacks Rank of 1 (Strong Buy) due to favorable earnings estimate revisions from analysts [8] - The stock has a Value Score of A, a Growth Score of A, and a Momentum Score of D, resulting in a combined VGM Score of A [6][8] Industry Comparison - In comparison, Perrigo Company plc (PRGO) has a Zacks Rank of 2 (Buy) and a Value Score of A, with earnings expected to be $3.03 per share on revenues of $4.44 billion for the current fiscal year [9][10] - PRGO shares have gained 3.4% over the past month, trading at a forward P/E of 9.06X and a P/CF of 5.43X [11]